BACKGROUND: In previous experimental models, because of its ability to inhibit the activity of platelet-derived growth factor beta receptor, imatinib decreased the interstitial fluid pressure and improved the delivery and efficacy of anticancer drugs, including fluorouracil. The objective of this Phase I study was to define the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of imatinib in combination with fluorouracil and leucovorin in patients with chemotherapy-refractory gastrointestinal cancer. METHODS: A 3-patient cohort dose-escalating study design was used. Patients received leucovorin 200 mg/m2 followed by fluorouracil 2000 mg/m2 as a 24-hour infusion on Days 1 and 2 combined with imatinib on Days -4, -3, -2, -1, 1, 2, 3, and 4. Cycles were repeated every 2 weeks, and the imatinib dose was escalated from 300 mg daily to 700 mg daily in 100-mg steps. RESULTS: Thirty patients were enrolled at 5 dose levels. Frequent and dose-dependant National Cancer Institute Common Toxicity Criteria grade 1-4 adverse events with suspected relation to the treatment were anemia (43%), nausea (33%), fluid retention (27%), elevated serum gamma-glutamyl-transpeptidase (20%), and diarrhea. DLTs were severe neutropenia, central fluid retention, and severe nausea observed in 1 patient each, resulting in an MTD for imatinib of 600 mg per day. There were no differences in imatinib pharmacokinetics before or during chemotherapy. A minor response was observed; and signs of clinical activity, including the resolution of ascites and improvement in performance status, were noted in some patients. CONCLUSIONS: The combination of biweekly fluorouracil/leucovorin and imatinib 600 mg daily given in a week-on/week-off schedule was feasible and safe. Nausea and fluid retention represented the DLTs. Copyright (c) 2007 American Cancer Society
BACKGROUND: In previous experimental models, because of its ability to inhibit the activity of platelet-derived growth factor beta receptor, imatinib decreased the interstitial fluid pressure and improved the delivery and efficacy of anticancer drugs, including fluorouracil. The objective of this Phase I study was to define the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of imatinib in combination with fluorouracil and leucovorin in patients with chemotherapy-refractory gastrointestinal cancer. METHODS: A 3-patient cohort dose-escalating study design was used. Patients received leucovorin 200 mg/m2 followed by fluorouracil 2000 mg/m2 as a 24-hour infusion on Days 1 and 2 combined with imatinib on Days -4, -3, -2, -1, 1, 2, 3, and 4. Cycles were repeated every 2 weeks, and the imatinib dose was escalated from 300 mg daily to 700 mg daily in 100-mg steps. RESULTS: Thirty patients were enrolled at 5 dose levels. Frequent and dose-dependant National Cancer Institute Common Toxicity Criteria grade 1-4 adverse events with suspected relation to the treatment were anemia (43%), nausea (33%), fluid retention (27%), elevated serum gamma-glutamyl-transpeptidase (20%), and diarrhea. DLTs were severe neutropenia, central fluid retention, and severe nausea observed in 1 patient each, resulting in an MTD for imatinib of 600 mg per day. There were no differences in imatinib pharmacokinetics before or during chemotherapy. A minor response was observed; and signs of clinical activity, including the resolution of ascites and improvement in performance status, were noted in some patients. CONCLUSIONS: The combination of biweekly fluorouracil/leucovorin and imatinib 600 mg daily given in a week-on/week-off schedule was feasible and safe. Nausea and fluid retention represented the DLTs. Copyright (c) 2007 American Cancer Society
Authors: Michael J Pishvaian; Rebecca Slack; Eunice Y Koh; Jan H Beumer; Marion L Hartley; Ion Cotarla; John Deeken; Aiwu Ruth He; Jimmy Hwang; Shakun Malik; Kashif Firozvi; Minetta Liu; Beth Elston; Sandy Strychor; Merrill J Egorin; John L Marshall Journal: Cancer Chemother Pharmacol Date: 2012-09-27 Impact factor: 3.333
Authors: Andreas-Claudius Hoffmann; Ryutaro Mori; Daniel Vallbohmer; Jan Brabender; Uta Drebber; Stephan E Baldus; Ellen Klein; Mizutomo Azuma; Ralf Metzger; Christina Hoffmann; Arnulf H Hoelscher; Kathleen D Danenberg; Klaus L Prenzel; Peter V Danenberg Journal: J Gastrointest Surg Date: 2008-08-13 Impact factor: 3.452
Authors: Patricia Lorusso; Elisabeth I Heath; Jesse McGreivy; Yu-Nien Sun; Rebeca Melara; Lucy Yan; Lisa Malburg; Megan Ingram; Jeffrey Wiezorek; Li Chen; Mary Jo Pilat Journal: Invest New Drugs Date: 2008-06-24 Impact factor: 3.850
Authors: Andreas-Claudius Hoffmann; Ryutaro Mori; Daniel Vallbohmer; Jan Brabender; Ellen Klein; Uta Drebber; Stephan E Baldus; Janine Cooc; Mizutomo Azuma; Ralf Metzger; Arnulf H Hoelscher; Kathleen D Danenberg; Klaus L Prenzel; Peter V Danenberg Journal: Neoplasia Date: 2008-07 Impact factor: 5.715
Authors: M Sahraei; L D Roy; J M Curry; T L Teresa; S Nath; D Besmer; A Kidiyoor; R Dalia; S J Gendler; P Mukherjee Journal: Oncogene Date: 2012-01-23 Impact factor: 9.867
Authors: Stephen F Madden; Colin Clarke; Patricia Gaule; Sinead T Aherne; Norma O'Donovan; Martin Clynes; John Crown; William M Gallagher Journal: Breast Cancer Res Date: 2013 Impact factor: 6.466
Authors: Martina Mayr; Karen Becker; Nadine Schulte; Sebastian Belle; Ralf Hofheinz; Annekatrin Krause; Roland M Schmid; Christoph Röcken; Matthias P Ebert Journal: BMC Cancer Date: 2012-12-10 Impact factor: 4.430
Authors: T Hoehler; G von Wichert; C Schimanski; S Kanzler; M H Moehler; A Hinke; T Seufferlein; J Siebler; A Hochhaus; D Arnold; M Hallek; R Hofheinz; U T Hacker Journal: Br J Cancer Date: 2013-08-20 Impact factor: 7.640